ストックスクリーナーアプリを入手
0.9457
6.83%
-0.0693
アフターアワーズ：
.95
0.0043
+0.45%
前日終値:
$1.015
開ける：
$1.01
24時間の取引高:
218.35K
Relative Volume:
0.92
時価総額：
$56.11M
収益：
$96.63M
当期純損益:
$-63.32M
株価収益率:
-0.6477
EPS:
-1.46
ネットキャッシュフロー:
$-54.55M
1週間 パフォーマンス:
-15.94%
1か月 パフォーマンス:
-24.34%
6か月 パフォーマンス:
-69.79%
1年 パフォーマンス:
-67.39%
1日の値動き範囲:
$0.9457
$1.05
1週間の範囲:
$0.9457
$1.26
52週間の値動き範囲:
$0.9457
$3.42
Akoya Biosciences Inc Stock (AKYA) Company Profile
AKYA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AKYA
Akoya Biosciences Inc
|
0.9457 | 56.11M | 96.63M | -63.32M | -54.55M | -1.46 |
|
ISRG
Intuitive Surgical Inc
|
565.94 | 192.17B | 8.71B | 2.48B | 1.75B | 6.82 |
|
BDX
Becton Dickinson Co
|
171.02 | 47.90B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ALC
Alcon Inc
|
87.24 | 47.53B | 9.93B | 1.12B | 1.58B | 2.25 |
|
RMD
Resmed Inc
|
246.99 | 35.88B | 5.02B | 1.31B | 1.56B | 8.91 |
|
COO
The Cooper Companies, Inc.
|
80.47 | 16.25B | 3.93B | 415.40M | 384.70M | 2.06 |
Akoya Biosciences Inc Stock (AKYA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-15 | ダウングレード | Craig Hallum | Buy → Hold |
| 2024-08-06 | ダウングレード | BTIG Research | Buy → Neutral |
| 2024-08-06 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-08-06 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-21 | 開始されました | Craig Hallum | Buy |
| 2023-12-14 | 開始されました | Guggenheim | Neutral |
| 2023-07-05 | 再開されました | JP Morgan | Overweight |
| 2023-02-02 | 開始されました | UBS | Buy |
| 2022-11-03 | 開始されました | CapitalOne | Overweight |
| 2022-10-06 | 開始されました | Stephens | Overweight |
| 2022-06-22 | 開始されました | BTIG Research | Buy |
| 2022-01-06 | 再開されました | Piper Sandler | Overweight |
| 2021-05-11 | 開始されました | Canaccord Genuity | Buy |
| 2021-05-11 | 開始されました | JP Morgan | Overweight |
| 2021-05-11 | 開始されました | Morgan Stanley | Overweight |
| 2021-05-11 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Akoya Biosciences Inc (AKYA) 最新ニュース
Akoya Biosciences (AKYA) Faces Uncertainty Amid Merger and Marke - GuruFocus
Akoya Biosciences, Inc. SEC 10-Q Report - TradingView
Akoya: Q1 Earnings Snapshot - The Washington Post
Akoya Biosciences earnings missed by $0.11, revenue fell short of estimates - Investing.com Canada
Akoya Biosciences (AKYA) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Akoya Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Akoya Biosciences Reports First Quarter 2025 Financial Results - The Manila Times
Akoya Biosciences (AKYA) Projected to Post Quarterly Earnings on Monday - Defense World
AKOYA BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akoya Biosciences, Inc.AKYA - Business Wire
Akoya Biosciences, Inc. (NASDAQ:AKYA) Shares Acquired by JPMorgan Chase & Co. - Defense World
Quanterix and Akoya Biosciences Announce Amended Merger Agreement - ADVFN
Akoya Biosciences (AKYA) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - Yahoo Finance
Akoya Biosciences, Inc. (NASDAQ:AKYA) Receives Average Recommendation of “Hold” from Brokerages - The AM Reporter
Canaccord Genuity Group Has Lowered Expectations for Akoya Biosciences (NASDAQ:AKYA) Stock Price - Defense World
AKYA Merger Faces Backlash Amid Shareholder Discontent | AKYA St - GuruFocus
Quanterix Acquisition of Akoya Biosciences (AKYA) Faces Challenges | AKYA Stock News - GuruFocus
Kent Lake Issues Statement on Quanterix?s Amendment to Merger with Akoya Biosciences - marketscreener.com
Quanterix, Akoya Biosciences Amend Merger Deal - marketscreener.com
Akoya stock falls on amended Quanterix merger deal (AKYA) - Seeking Alpha
Quanterix Revises Merger Terms with Akoya Biosciences - TipRanks
Merger Amendment: Changes to Quanterix and Akoya Biosciences (AK - GuruFocus
Quanterix And Akoya Biosciences Announce Amended Merger Agreement - marketscreener.com
Canaccord Adjusts Price Target for Akoya Biosciences (AKYA) | AK - GuruFocus
$HAREHOLDER ALERT: The M&A Class Action Firm Urges Stockholders of AKYA, WTMA, PLYA, QTRX to Act Now - GlobeNewswire Inc.
Akoya Biosciences introduces new assay for breast cancer ADC development By Investing.com - Investing.com South Africa
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Pacific Premier Bancorp, Inc. (NasdaqPPBI), Southern States Bancshares, Inc. (NasdaqSSBK), Akoya Biosciences, Inc. (NasdaqAKYA) - TradingView
Akoya Biosciences (AKYA) Unveils New Assay for Breast Cancer Res - GuruFocus
Akoya Biosciences (AKYA) Unveils New Assay for Breast Cancer Research | AKYA Stock News - GuruFocus
Akoya Biosciences introduces new assay for breast cancer ADC development - Investing.com Australia
Akoya Biosciences Expands Biopharma Service Portfolio with New ADC Breast Cancer Assay and Real-world IO60 Insights at AACR 2025 - The Manila Times
Akoya Biosciences Expands Biopharma Service Portfolio with - GlobeNewswire
Akoya Biosciences and Enable Medicine Launch the Largest - GlobeNewswire
Revolutionary Cancer Research: 100M+ Cells Atlas Unlocks New Era in Biomarker Discovery - Stock Titan
Akoya Biosciences Collaborates with Singapore Translational Cancer Consortium on SUPER Study to Enhance Immunotherapy Response Analysis - Nasdaq
Akoya Biosciences and Singapore Translational Cancer - GlobeNewswire
Major Cancer Research Breakthrough: How 200 Patient Study Could Transform Immunotherapy Treatment Success - Stock Titan
$TOCKHOLDER ALERT: The M&A Class Action Firm Encourages Shareholders of GB, YOTA, PORT, AKYA to Act - The Malaysian Reserve
7.7% Stakeholder Fights Quanterix-Akoya Merger: Claims Board Conflicts and Shareholder Value Destruction - Stock Titan
Akoya Biosciences (NASDAQ:AKYA) Given New $1.65 Price Target at Piper Sandler - Defense World
Tikvah Management Calls on Quanterix to Explain the Egregious Te - GuruFocus
Tikvah Management Calls on Quanterix to Explain the Egregious Terms of Convertible Notes Purchased from Akoya Biosciences - Bluefield Daily Telegraph
Quanterix Faces Investor Backlash: $30M Convertible Notes Deal Under Fire - Stock Titan
Akoya Biosciences, Inc. (NASDAQ:AKYA) Given Consensus Recommendation of “Hold” by Analysts - Defense World
Akoya Biosciences stock hits 52-week low at $1.07 amid market challenges By Investing.com - Investing.com South Africa
Akoya Biosciences stock hits 52-week low at $1.07 amid market challenges - Investing.com India
Quanterix Under Fire: Top Investor Warns of 'Value Destructive' $30M Deal with Struggling Akoya - Stock Titan
Akoya BiosciencesOn April 2, Entered Securities Purchase Agreement With Quanterix Corporation - MarketScreener
Spatial Genomics and Transcriptomics Industry Analysis Report 2025, Featuring Detailed Profiles of Leading Players10x Genomics, Bruker Corp., Akoya Biosciences, and Bio-Techne Among OthersResearchAndMarkets.com - Bluefield Daily Telegraph
Akoya Biosciences and Team SAMBAI Announce Selection of the - GlobeNewswire
Akoya Biosciences And Team SAMBAI Select PhenoCycler-Fusion For Cancer Equity Research - Nasdaq
Akoya Biosciences Inc (AKYA) 財務データ
収益
当期純利益
現金流量
EPS
3.24%
大文字化:
|
ボリューム (24 時間):